BiotechTube
Versameb

Versameb

Basel, Switzerland· Est.
versameb.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $43M

Overview

Versameb is an early-stage, privately held biotech company pioneering next-generation RNA therapeutics from its base in Basel, Switzerland. The company's core innovation is the VERSagile platform, designed to optimize functional mRNA for novel disease applications, including multi-target modulation. While still in a pre-clinical or early discovery stage, Versameb aims to address genetic diseases through its RNA-based approach and has been supported by the Basel-area accelerator BaseLaunch. The company represents a specialized player in the competitive but high-potential field of advanced RNA therapeutics.

Genetic Diseases

Technology Platform

VERSagile platform for optimizing functional mRNA application, enabling multi-target modulation with a single RNA construct.

Funding History

2
Total raised:$43M
Series A$35M
Seed$8M

Opportunities

The growing RNA therapeutics market and demand for novel modalities that can address complex, multi-factorial genetic diseases present a significant opportunity.
Versameb's location in the Basel biotech hub facilitates access to partnership and investment from major pharmaceutical companies.

Risk Factors

High technical risk associated with developing a novel, multi-target RNA platform and achieving effective delivery.
Significant financial risk as a pre-revenue company requiring substantial capital to advance to clinical stages, amid intense competition in the RNA field.

Competitive Landscape

Versameb operates in a highly competitive landscape dominated by large mRNA players (e.g., Moderna, BioNTech) and numerous biotechs focused on RNA delivery and engineering. Its differentiation hinges on its claimed ability for controlled, multi-target modulation, a niche yet unproven approach.

More companies in Switzerland →